Ownership Breakdown
| Retail Investors40.52% | Institutions58.38% |
| Retail Investors | 40.52 | |
| Insiders | 1.1 | |
| Institutions | 58.38 |
Will Freeline TherapeuticsHold (USA Stocks:FRLN) turn things around in August?
 | By Vlad Skutelnik | Macroaxis Story |
Freeline Therapeutics Holdings Plc (NASDAQ: FRLN), a key player in the Biotechnology industry, has been showing bullish momentum recently. Despite an operating loss of $98.4M and a net income loss of $89M, the company's real value stands at $10.05, indicating potential for growth. The company's EPS estimate for the next year is -$5.21, while the current quarter's estimate is -$3.1. Analysts have a consensus to 'Buy' with an estimated target price of $24.406, with the highest estimate reaching $74.626. This suggests a possible upside price of $15.36, significantly higher than the current market valuation of $5.75. However, the lowest estimated target price stands at $3, indicating a possible downside risk of 0.0575. Freeline Therapeutics, with a market capitalization of $16.1M and an enterprise value.of -$38.1M, operates in the Healthcare sector, specifically in Pharmaceuticals, Biotechnology & Life Sciences. With 152 full-time employees, the company's financial health is supported by a book value of $12.89 and an interest income of $904K. Given these factors, it is crucial for investors to monitor Freeline Therapeutics' performance in August to determine if the bullish momentum will continue. More information can be found on their website [here](https://www.freeline.life). The current ratio of Freeline Therapeutics Holdings Plc remains stable at present, compared to the previous year. The company reported a current ratio of 2.18 last year. As of July 13, 2023, the Debt to Equity Ratio is projected to increase to 0.71, while Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) are expected to decrease by 93.7 million. As interest in the biotechnology sector continues to grow, it's worthwhile to examine Freeline Therapeutics Holdings Plc in more detail. Despite current challenges, there is still confidence in a swift recovery. In this article, I will also review some crucial indicators that investors in Freeline Therapeutics Holdings should consider in August.
Macroaxis uses a strict editorial review process to publish stories and blog posts. Our publishers support our company and may receive a small commission when the partner links or references are utilized. Commissions do not affect the opinions or evaluations of our editorial team. The information our editors and media partners deliver is confidential and licensed for your sole use as a Macroaxis user. We reserve all rights to the content of this article, and therefore copying or distributing this story in whole or in part is strictly prohibited.
Reviewed by Michael Smolkin
Freeline Therapeutics Holdings Plc is currently undervalued at $10.05 per share, with modest growth projections. The company holds a performance score of 2 on a scale of 0 to 100. It has a Beta (market volatility) of 2.6536, indicating a relatively high risk compared to the market. This Beta suggests that as the market rises, Freeline is expected to outperform it. Conversely, if the market yields negative returns, Freeline is likely to underperform.
While it's crucial to consider Freeline's historical returns, it's also wise to be cautious about using this information to predict current trending patterns in the company's equity. The best approach to forecasting the future performance of any stock is to evaluate the business as a whole, taking into account its past performance and all available fundamental and technical indicators.
A review of Freeline's technical indicators can help determine whether the expected return of 0.33% is sustainable in the future. Please use Freeline's variance, as well as the relationship between the value at risk and skewness, to make a quick decision on whether Freeline's price patterns will revert.
Additional examination
Freeline Therapeutics Holdings Plc (FRLN), a prominent player in the Healthcare and Biotechnology industry, has been maintaining a bullish momentum in the market. The company's net income from continuing operations stands at a loss of 89M, and an EBITDA of -84.7M, indicating significant financial challenges. Despite these losses, the stock has seen a price percent change of 54.99, reflecting a strong market performance. However, with a high total risk alpha of -0.24 and a standard deviation of 10.12, investors should be cautious of potential volatility. The company's last price was 5.75, which is considerably lower than the Wall Street target price of 13.25, suggesting potential upside for investors. The performance of Freeline Therapeutics Holdings in the marketplace will significantly impact your decision to invest in its stock. Revenue growth, profitability, competitive positioning, management quality, and industry trends can influence Freeline Therapeutics' stock prices. When investing in Freeline Therapeutics, there are several factors to consider and potential outcomes to expect. As a company performs well, its stock price may increase, allowing investors to benefit from price appreciation. However, Freeline Stock can experience significant price fluctuations due to market conditions, economic factors, industry trends, or company-specific news. This is why investing in stocks such as Freeline Therapeutics carries risks, including the potential for capital loss. Stock prices can decline, and investors may incur losses if they sell shares at a lower price than their initial investment.How important is Freeline Therapeutics's Liquidity
Freeline Therapeutics financial leverage refers to using borrowed capital as a funding source to finance Freeline Therapeutics Holdings ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Freeline Therapeutics financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Freeline Therapeutics' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Freeline Therapeutics' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the breakdown between Freeline Therapeutics's total debt and its cash.
An Additional Perspective On Freeline Therapeutics
The market capitalization of Freeline TherapeuticsHold is $16.11 Million. Over half of Freeline TherapeuticsHold outstanding shares are owned by other corporate entities. These other corporate entities are typically referred to corporate investors that obtain positions in a given instrument to benefit from reduced trade commissions. Consequently, these institutional investors. class="underlinedLink" href="/invest/ratio/FRLN/Shares-Owned-by-Institutions">institutions are subject to different rules and regulation than regular investors in Freeline TherapeuticsHold. Please watch out for any change in the institutional holdings of Freeline TherapeuticsHold as this could mean something significant has changed or about to change at the company. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Freeline Therapeutics Holdings Plc (NASDAQ: FRLN), a notable player in the Biotechnology industry, has been gaining attention from investors with its recent bullish momentum. As of July 2023, the company has a significant current ratio of 3.68X and a book value of 12.89, suggesting a solid financial position.However, the company's EPS estimate for the current year stands at a loss of 13.96, which may cause concern for some investors. Despite the losses, Freeline Therapeutics Holdings Plc maintains a strong market presence with a Wall Street target price of 13.25 and a price to book ratio of 0.56X. The company also boasts a substantial enterprise value.to EBITDA ratio of 0.1459, indicating its potential for future growth. However, the company's high probability of bankruptcy at 96.00% and a Z score of -8.76 are red flags that investors should not overlook. Moreover, the company has a downside deviation of 6.52 and a downside variance of 42.45, suggesting a high level of risk. Freeline Therapeutics Holdings Plc has a robust workforce of 152 full-time employees and a significant number of shares owned by institutions at 58.38%. With a substantial amount of cash and equivalents totaling $90M, the company appears to be well-positioned to maintain its bullish momentum in August. However, investors should be cautious given the company's high risk and potential for bankruptcy. .
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Freeline Therapeutics Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.